• Professor, Department of Radiation Oncology, Harvard Medical School
• Director, Translational Research, Radiation Oncology, Dana-Farber Cancer Institute
• Associate in Medicine, Hematology/Oncology, Boston Children's Hospital
Dr Guinan received the Clare and Richard Morse Research Award, 2000 and the Clinical Translational Scientist Award, Burroughs Wellcome, 1999.
Dr Guinan's research focuses on overcoming problems related to allogenicity in transplantation. Allogeneic transplantation is limited, in large part, by the ability to find donors of suitable histocompatibility. Global immunosuppression has been an incomplete and highly toxic approach to this problem. Current understanding of T cell activation suggests that blocking B7-CD28 interactions of the costimulatory pathway for human T helper cells may provide an innovative and effective way of producing antigen-specific T cell hyporesponsiveness. Guinan and colleagues are applying these various strategies to the transplant setting.
Another area of active investigation is the impact of genetic makeup on risk for regimen-related toxicity during transplantation and the development of novel agents for prevention or treatment of regimen-related toxicity.
In the role of Faculty Member, Eva Guinan contributes recommendations and reviews to the Pediatric Hematology Section in the Hematology Faculty, writing brief accessible comments to summarize the value of the articles and adding rating score.
The Faculty comprises Heads of Faculty, Heads of Section, Faculty Members and Associate Faculty Members, as well as an International Advisory Board.
Read more about F1000Prime »